达格列净在不同衰弱程度的慢性肾病患者中的疗效与安全性
结果显示,达格列净在所有衰弱类别中均一致降低主要复合终点风险,且严重不良事件数值上更低,安全性无差异。
要点
- 达格列净在非轻度、中度和重度衰弱患者中均降低主要复合终点风险,交互作用不显著。
- 肾脏复合终点、心血管终点和全因死亡在各衰弱类别中结果一致。
- 严重不良事件在达格列净组数值上低于安慰剂组,各衰弱类别安全性无差异。
核心结论
- 达格列净对慢性肾病患者所有结局的相对获益在各衰弱类别中一致,且安全性无差异。
主要发现
- 达格列净降低主要复合终点(持续eGFR下降≥50%、终末期肾病或肾脏/心血管死亡)的风险比在非轻度、中度和重度衰弱组分别为0.50(95%CI 0.33-0.76)、0.62(95%CI 0.45-0.85)和0.64(95%CI 0.49-0.83),交互作用P=0.67。
- 严重不良事件发生率在达格列净组与安慰剂组分别为:非轻度衰弱16.9% vs 20.1%,中度衰弱26.3% vs 30.7%,重度衰弱42.9% vs 47.8%。
关键数值与推荐
- 衰弱指数(FI)分组标准:非轻度衰弱FI≤0.210(27.0%),中度衰弱FI 0.211-0.310(38.2%),重度衰弱FI>0.311(34.8%)。
- 干预:达格列净10 mg/天或安慰剂。
临床怎么用
- 对于合并慢性肾病的老年患者,无论衰弱程度如何,达格列净的肾脏和心血管获益一致,且未增加严重不良事件风险。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A sizeable proportion of patients with chronic kidney disease (CKD) are reported to be frail. Here we examined the safety and efficacy of dapagliflozin in patients with CKD by frailty level. METHODS: Adults with CKD, with/without type 2 diabetes, with an estimated glomerular filtration rate (eGFR) of 25-75 mL/min/1.73 m2, and urinary albumin-to-creatinine ratio 200-5 000 mg/g were randomized to dapagliflozin (10 mg/day) or placebo. The primary endpoint was a composite of sustained ≥50% eGFR decline, end-stage kidney disease (ESKD), or death from kidney or cardiovascular (CV) causes. RESULTS: Frailty index (FI), assessed by Rockwood cumulative deficit approach, was calculable in 4 303/4 304 (99.9%) patients: 1 162 (27.0%) in not-to-mildly frail (FI ≤0.210), 1 642 (38.2%) in moderately frail (FI 0.211-0.310), and 1 499 (34.8%) in severely frail categories (FI >0.311). Dapagliflozin reduced the risk of the primary composite endpoint across all FI categories (hazard ratios [95% confidence interval {CI}]: 0.50 [0.33-0.76], 0.62 [0.45-0.85], and 0.64 [0.49--0.83], respectively; p-interaction = 0.67). Results were similar for secondary outcomes including kidney composite outcome (sustained ≥50% eGFR decline, ESKD or death from kidney cause; p-interaction = 0.44), CV endpoint (heart failure hospitalization or CV death; p-interaction = 0.63), and all-cause mortality (p-interaction p = .42). Results were consistent when using FI as a continuous variable. Occurrence of serious adverse events was numerically lower in patients receiving dapagliflozin versus placebo in all FI categories (16.9% vs 20.1%, 26.3% vs 30.7%, and 42.9% vs 47.8%, in not-to-mildly, moderately, and severely frail categories, respectively). CONCLUSIONS: The relative benefit of dapagliflozin for all outcomes was consistent across all frailty categories, with no difference in associated safety.
引用
- Vart P, Butt JH, Jongs N, et al. Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty. J Gerontol A Biol Sci Med Sci. 2024. PMID: 37527836. doi:10.1093/gerona/glad181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。